Item 9A. Controls and Procedures
ITEM 9A.
CONTROLS AND PROCEDURES
Disclosure
controls and procedures are designed to ensure that information required to be disclosed in our reports filed or submitted under the
Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms and
is accumulated and communicated to the Company’s management, as appropriate, in order to allow timely decisions in connection with
required disclosure.
Evaluation
of Disclosure Controls and Procedures
Under
the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer,
Mr. Ajjarapu and Ms. Huffman, respectively, we conducted an evaluation of the effectiveness of the design and operation of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this
Annual Report (December 31, 2022). Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer
concluded that as of December 31, 2022, our disclosure controls and procedures were not effective to provide reasonable assurance
that information required to be disclosed in our reports filed with the SEC pursuant to the Exchange Act, is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated
to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures.
As
a result of the formative stage of our development, the Company has not fully implemented the necessary internal controls. The matters
involving internal controls and procedures that the Company’s management considered to be material weaknesses under the standards
of the Committee of Sponsoring Organizations of the Treadway Commission (COSO) were: (1) The Company did not maintain a fully integrated
financial consolidation and reporting system throughout the period and as a result, extensive manual analysis, reconciliation and adjustments
were required in order to produce financial statements for external reporting purposes. and (2) The Company does not currently have a
sufficient complement of technical accounting and external reporting personnel commensurate to support standalone external financial
reporting under public company or SEC requirements. Specifically, the Company did not effectively segregate certain accounting duties
due to the small size of its accounting staff and maintain a sufficient number of adequately trained personnel necessary to anticipate
and identify risks critical to financial reporting and the closing process. In addition, there were inadequate reviews and approvals
by the Company’s personnel of certain reconciliations and other processes in day-to-day operations due to the lack of a full complement
of accounting staff.
Management
believes that the material weaknesses set forth above did not have an effect on the Company’s financial results reported herein.
We are committed to improving our financial organization. As part of this commitment, we have increased our personnel resources and technical
accounting expertise as we develop the internal and financial resources of the Company. In addition, the Company has prepared and implemented
sufficient written policies and checklists which will set forth procedures for accounting and financial reporting with respect to the
requirements and application of GAAP and SEC disclosure requirements.
Management
has prepared and is in the process of implementing sufficient written policies and checklists to remedy the following material weaknesses
(i) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application
of GAAP and SEC disclosure requirements; and (ii) ineffective controls over period end financial close and reporting processes.
We
have improved our financial organization as we have increased our personnel resources and technical accounting expertise. We will continue
to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting
on an ongoing basis.
Management’s
Report on Internal Control Over Financial Reporting
Management
of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. The Company’s internal control over financial reporting is designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with GAAP, but because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. The Company’s internal control over financial reporting includes those policies and procedures that are designed
to:
●
pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
assets of the Company;
●
provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors
of the Company; and
●
provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s
assets that could have a material effect on the financial statements.
86
Management
conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022.
In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
in Internal Control — Integrated Framework (2013). Based on our assessment, management concluded that the Company’s internal
controls over financial reporting were not effective as of December 31, 2022, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements in accordance with GAAP. Specifically, management’s determination
was based on the following material weaknesses which existed as of December 31, 2022:
●
Financial
Reporting Systems : The Company did not maintain a fully integrated financial consolidation and reporting system throughout the
period and as a result, extensive manual analysis, reconciliation and adjustments were required in order to produce financial statements
for external reporting purposes.
●
Segregation
of Duties : The Company does not currently have a sufficient complement of technical accounting and external reporting personnel
commensurate to support standalone external financial reporting under public company or SEC requirements. Specifically, the Company
did not effectively segregate certain accounting duties due to the small size of its accounting staff and maintain a sufficient number
of adequately trained personnel necessary to anticipate and identify risks critical to financial reporting and the closing process.
In addition, there were inadequate reviews and approvals by the Company’s personnel of certain reconciliations and other processes
in day-to-day operations due to the lack of a full complement of accounting staff.
Limitations
on the Effectiveness of Controls
Management
of the Company, including its Chief Executive Officer and its Chief Financial Officer, does not expect that the Company’s disclosure
controls and procedures or its internal control over financial reporting will prevent or detect all error and all fraud. A control system,
no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives
will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must
be considered relative to their costs. Furthermore, because of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud,
if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that
breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons or
by the collusion of two or more persons. The design of any system of controls is based in part on certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Projections of any evaluation of the effectiveness of controls to future periods are subject to risks. Over time, controls
may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
Changes
in Internal Control Over Financial Reporting.
There
have not been any changes in our internal control over financial reporting during the quarter ended December 31, 2022, that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
As
a result of COVID-19, our workforce operated primarily in a work from home environment for the year ended December 31, 2022.
While pre-existing controls were not specifically designed to operate in our current work-from-home operating environment, we do not
believe that such work-from-home actions have had a material adverse effect on our internal controls over financial reporting. We have
continued to re-evaluate and refine our financial reporting process to provide reasonable assurance that we could report our financial
results accurately and timely.
ITEM 9B.
OTHER INFORMATION
None.
ITEM 9C.
DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not
applicable.
87
PART
III
Information
required by Items 10, 11, 12, 13 and 14 of Part III is omitted from this Annual Report and will be filed in a definitive proxy statement
or by an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report (subject
to any extension provided by Exchange Act Rule 0-3).
ITEM 10.
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The
information required by this Item will be set forth in the Company’s 2023 Proxy Statement to be filed with the SEC within 120 days
after December 31, 2022 (subject to any extension provided by Exchange Act Rule 0-3) in connection with the solicitation of proxies for
the Company’s 2023 annual meeting of stockholders including under the headings “ Election of Directors ”, “ Information
about our Executive Officers ”, “ Corporate Governance ”, “ Code of Ethics ”, “ Committees
of the Board ”, and “ Delinquent Section 16(a) Reports ” (to the extent applicable and warranted), and is incorporated
herein by reference.
ITEM 11.
EXECUTIVE COMPENSATION
The
information required by this Item will be set forth in the Company’s 2023 Proxy Statement to be filed with the SEC within 120 days
after December 31, 2022 (subject to any extension provided by Exchange Act Rule 0-3) ,
including under the headings “ Executive Compensation ”, “ Directors Compensation ”, “ Outstanding
Equity Awards at Fiscal Year-End ”, “ Compensation Committee Interlocks and Insider Participation ” and “ Compensation
Committee Report ” (to the extent required), and is incorporated herein by reference.
ITEM 12.
SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The
information required by this Item will be set forth under the heading “ Voting Rights and Principal Stockholders ” and
“ Equity Compensation Plan Information ” in the Company’s 2023 Proxy Statement to be filed with the SEC within
120 days after December 31, 2022 (subject to any extension provided by Exchange Act
Rule 0-3) and is incorporated herein by reference.
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE
The
information required by this Item will be set forth in the Company’s 2023 Proxy Statement to be filed with the SEC within 120 days
after December 31, 2022 (subject to any extension provided by Exchange Act Rule 0-3) ,
including under the headings “ Certain Relationships and Related Transactions ” and “ Committees of the Board ”
- “ Director Independence ”, and is incorporated herein by reference.
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES
The
information required by this Item will be set forth under the heading “ Ratification of Appointment of Auditors ” -
“ Audit Fees ” in the Company’s 2023 Proxy Statement to be filed with the SEC within 120 days after December 31,
2022 (subject to any extension provided by Exchange Act Rule 0-3) , and is incorporated herein by reference.
88
PART
IV
ITEM 15.
EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES
(a)
Documents filed as part of this Annual Report:
The
following is an index of the financial statements, schedules and exhibits included in this Form 10-K or incorporated herein by reference.
(1)
All Financial Statements
Index to Consolidated
Financial Statements
Report of Independent Registered Public Accounting Firm
65
Consolidated Balance Sheets
66
Consolidated Statements of Operations
67
Consolidated Statements of Changes in Stockholders’ Equity
68
Consolidated Statements of Cash Flows
69
Notes to Consolidated Financial Statements
70
(2)
Consolidated Financial
Statement Schedules
Except
as provided above, all financial statement schedules have been omitted, since the required information is not applicable or is not present
in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial
statements and notes thereto included in this Form 10-K.
(3)
Exhibits
Incorporated
by Reference
Exhibit
No.
Description
Form
File
No.
Exhibit
Filing
Date
Filed/Furnished
Herewith
1.1
Equity Distribution Agreement, dated August 6, 2021 between the Company and EF Hutton, division of Benchmark Investments, LLC
8-K
001-39199
1.1
8/6/2021
3.1
Second Amended and Restated Certificate of Incorporation of Trxade Group, Inc.
S-1
333-234221
3.1
10/15/2019
3.3
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (1-for-6 Reverse Stock Split of Common Stock) filed with the Delaware Secretary of State on February 12, 2020, and effective February 13, 2020
8-K
001-39199
3.1
2/13/2020
3.4
Certificate of Amendment of Certificate of Incorporation (changing name TRxADE HEALTH, INC.)
8-K
001-39199
3.1
5/28/2021
3.5
Limited Liability Company Agreement of SOSRx LLC effective February 15, 2022
8-K
001-39199
3.1
2/16/2022
3.6
Amended and Restated Bylaws of Trxade Group, Inc.
10-12G/A
000-55218
3.1
7/24/2014
4.1*
Description of Registered Securities
X
10.1
$300,000 Promissory Note dated October 15, 2018 with Nikul Panchal
8-K
000-55218
2.02
10/16/2018
10.2
Revocable Warrant dated October 15, 2018 with Nikul Panchal
8-K
000-55218
2.03
10/16/2018
10.3***
Indemnification Agreement dated February 6, 2019 with Prashant Patel and Suren Ajjarapu
10-K
000-55218
10.1
3/22/2019
10.4
Form of Investment Warrant Agreement
8-K
000-55218
10.2
7/13/2018
10.5
Form of Warrant Agreement
8-K
000-55218
10.2
9/26/2014
10.6
Form of Registration Rights Agreement
8-K
000-55218
10.3
9/26/2014
10.7***
Employment Agreement between Trxade, Inc. and Prashant Patel dated May 24, 2013
10-12G/A
000-55218
10.6
7/24/2014
10.8***
2014 Equity Incentive Plan
10-12G
000-55218
10.3
6/11/2014
10.9***
Form of Indemnification Agreement entered into between Trxade Group, Inc. and its directors and certain officers
10-12G
000-55218
10.4
6/11/2014
10.10***
Second Amended and Restated Trxade Group, Inc. 2019 Equity Incentive Plan
8-K
001-39199
10.1
5/28/2021
10.11***
Form of Stock Option Agreement (April 2020 Grants to Employees) April 14, 2020
8-K
001-39199
10.2
4/16/2020
10.12***
Form of Restricted Stock Grant Agreement (Independent Directors 2020 Award, 2020 CFO Award and 2020 Legal Counsel) April 14, 2020
8-K
001-39199
10.3
4/16/2020
89
10.13***
April 14, 2020 Executive Employment Agreement with Suren Ajjarapu
8-K
001-39199
10.4
4/16/2020
10.14***
First Amendment to Executive Employment Agreement with Suren Ajjarapu dated May 5, 2020
8-K
001-39199
10.2
5/7/2020
10.15***
Restricted Stock Grant Agreement (Mr. Ajjarapu 2020 Performance Bonus)(Updated) May 5, 2020
8-K
001-39199
10.3
5/7/2020
10.16***
Executive Employment Agreement dated effective June 19, 2020, entered into by and between Trxade Group, Inc. and Howard A. Doss
8-K
001-39199
10.1
6/26/2020
10.17***
Trxade Group, Inc. Independent Director Compensation Policy adopted April 14, 2020
10-Q
001-39199
10.1
7/27/2020
10.18***
Form of First Amendment to Trxade Group, Inc. 2019 Equity Incentive Plan Restricted Stock Grant Agreement (April 2020 Grants to Employees; Independent Directors 2020 Award, 2020 CFO Award and 2020 Legal Counsel Award)
8-K
001-39199
10.4
8/4/2020
10.19***
Form of Stock Option Agreement Trxade Group, Inc. Amended and Restated 2019 Equity Incentive Plan
S-8
333-246318
10.6
8/14/2020
10.20***
Form of Restricted Stock Grant Agreement Trxade Group, Inc. Amended and Restated 2019 Equity Incentive Plan
S-8
333-246318
10.7
8/14/2020
10.21***
Form of Trxade Group, Inc. 2019 Equity Incentive Plan Restricted Stock Grant Agreement
S-8
333-246318
10.8
8/14/2020
10.22
Non-Recourse Promissory Note in the amount of $500,000, dated February 15, 2022, by TRxADE HEALTH, INC. in favor of Exchange Health, LLC
8-K
001-39199
10.4
2/16/2022
10.23
Distribution Services Agreement dated February 15, 2022, by and between SOSRx LLC and Integra Pharma Solutions LLC
8-K
001-39199
10.4
2/16/2022
10.24
Member Asset Contribution Agreement dated February 15, 2022, between Exchange Health, LLC and SOSRx LLC
8-K
001-39199
10.4
2/16/2022
14.1
Code of Ethics
10-K
000-55218
14.1
3/23/2015
21.1*
List of Subsidiaries
X
23.1*
Consent of Independent Registered Accounting Firm
X
31.1*
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act*
X
31.2*
Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act*
X
32.1**
Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act**
X
32.2**
Certification of Principal Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act**
X
101.INS
Inline XBRL Instance Document - the instance document
does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
X
101.SCH
Inline XBRL
Taxonomy Extension Schema Document
X
101.CAL
Inline XBRL
Taxonomy Extension Calculation Linkbase Document
X
101.DEF
Inline XBRL
Taxonomy Extension Definition Linkbase Document
X
101.LAB
Inline XBRL
Taxonomy Extension Label Linkbase Document
X
101.PRE
Inline XBRL
Taxonomy Extension Presentation Linkbase Document
X
104
Inline XBRL for the cover page of this Annual Report
on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.
*
Filed herewith.
**
Furnished herewith.
***
Indicates management contract or compensatory plan
or arrangement.
ITEM 16.
FORM 10–K SUMMARY
None.
90
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
TRxADE HEALTH, INC.
Date: March 27, 2023
/s/ Suren
Ajjarapu
By:
Suren Ajjarapu, Chief Executive
Officer (Principal Executive Officer)
Date: March 27, 2023
/s/ Prashant
Patel
By:
Prashant
Patel
(Principal
Financial and Accounting Officer)
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Suren
Ajjarapu
Chairman of the Board, Chief Executive Officer and
Secretary
March 27, 2023
Suren Ajjarapu
(Principal Executive Officer)
/s/ Prashant
Patel
Director, President, Principal Accounting Officer and
Chief Operating Officer
March 27, 2023
Prashant Patel
/s/ Donald
G. Fell
Director
March 27, 2023
Donald G. Fell
/s/ Jeff
Newell
Director
March 27, 2023
Jeff Newell
/s/ Michael
L. Peterson
Director
March 27, 2023
Michael L. Peterson
91